Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Non-Current Liabilities: 2016-2025

Historic Other Non-Current Liabilities for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $5.2 million.

  • Akebia Therapeutics' Other Non-Current Liabilities rose 10.89% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 10.89%. This contributed to the annual value of $5.2 million for FY2024, which is 41.47% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Other Non-Current Liabilities is $5.2 million, which was down 63.08% from $14.2 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Other Non-Current Liabilities registered a high of $85.4 million during Q2 2021, and its lowest value of $4.7 million during Q3 2024.
  • In the last 3 years, Akebia Therapeutics' Other Non-Current Liabilities had a median value of $7.2 million in 2025 and averaged $9.3 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Other Non-Current Liabilities plummeted by 88.67% in 2023, and later skyrocketed by 116.56% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $84.2 million in 2021, then slumped by 81.34% to $15.7 million in 2022, then tumbled by 43.47% to $8.9 million in 2023, then tumbled by 41.47% to $5.2 million in 2024, then increased by 10.89% to $5.2 million in 2025.
  • Its Other Non-Current Liabilities was $5.2 million in Q3 2025, compared to $14.2 million in Q2 2025 and $7.2 million in Q1 2025.